View More View Less
  • 1 Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szeged, Állomás u 1., 6725
  • 2 Charles University Hospital, Plzeň

Absztrakt:

A vesesejtes carcinoma (RCC) többféle, a veséből kiinduló rosszindulatú daganattípus gyűjtőneve. Az egyes entitások sajátos epidemiológiai, morfológiai, immunhisztokémiai, genetikai és klinikai jellemvonásokkal bírnak. Ezek együttes figyelembevételével került publikálásra 2016-ban a vesedaganatok aktuális WHO-klasszifikációja. Az eltelt három év során újabb, provizórikus RCC-altípusok kerültek leírásra, melyek egyelőre nem képezik részét a hivatalos beosztásnak. Ebben az összefoglalóban ezek az entitások kerülnek részletes áttekintésre. A szerzők bemutatják a következő daganattípusok klinikopatológiai jellegzetességeit: pajzsmirigyszerű follicularis carcinoma, az ALK-transzlokációhoz társult carcinoma, vesesejtes carcinoma prominens simaizomstromával, fumarát-hidratáz-deficiens carcinoma, bifázisos squamoid papillaris carcinoma, eosinophil solid és cysticus carcinoma, atrophiás vesére emlékeztető carcinoma, világossejtes carcinoma óriássejtekkel és emperipolesissel, Warthin-szerű papillaris carcinoma, low-grade oncocytás vesetumor (CD117-negatív, CK7-pozitív), high-grade oncocytás vesetumor, TCEB1-mutáns carcinoma és neuroendokrin vonásokkal rendelkező chromophob carcinoma. Ha a patológus követi az aktuális leletezési protokollokat, akkor ezek az entitások jórészt nem osztályozható RCC-ként kerülnek diagnosztizálásra. A munka meg kívánja ismertetni ezeket az altípusokat a hazai patológus-, onkológus- és urológusközösséggel azért, hogy javuljon a diagnosztikus pontosság, valamint hogy elkezdődhessen az ilyen esetek gyűjtése és további célzott vizsgálata is. Orv Hetil. 2020; 161(3): 83–94.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Kovacs G, Akhtar M, Beckwith JB, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997; 183: 131–133.

  • 2

    Eble JN, Sauter G, Epstein JI, et al. (eds.) Pathology and genetics of tumors of the urinary system and male genital organs. International Agency for Research on Cancer, Lyon, 2004.

  • 3

    Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol. 2013; 37: 1469–1489.

  • 4

    Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013; 37: 1490–1504.

  • 5

    Trpkov K, Grignon DJ, Bonsib SM, et al. Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol. 2013; 37: 1505–1517.

  • 6

    Moch H, Humphrey PA, Ulbright TM, et al. (eds.) WHO classification of tumours of the urinary system and male genital organs. International Agency for Research on Cancer, Lyon, 2016.

  • 7

    Trpkov K, Hes O. New and emerging renal entities: a perspective post – WHO 2016 classification. Histopathology 2019; 74: 31–59.

  • 8

    Amin MB, Radhakrishnan A, Hes O, et al. Primary thyroid-like follicular carcinoma of the kidney: a histologically distinctive primary renal epithelial tumor. Mod Pathol. 2004; 17(Suppl 1): 136A.

  • 9

    Amin MB, Gupta R, Hes O, et al. Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm. Am J Surg Pathol. 2009; 33: 393–400.

  • 10

    Dhillon J, Tannir NM, Matin SF, et al. Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol. 2011; 42: 146–150.

  • 11

    Mano H. ALKoma: a cancer subtype with a shared target. Cancer Discov. 2012; 2: 495–502.

  • 12

    Cajaiba MM, Dyer LM, Geller JI, et al. The classification of pediatric and young adult renal cell carcinomas registered on the Children’s Oncology Group (COG) protocol AREN03B2 after focused genetic testing. Cancer 2018; 124: 3381–3389.

  • 13

    Cajaiba MM, Jennings LJ, Rohan SM, et al. ALK-rearranged renal cell carcinomas in children. Genes Chromosomes Cancer 2016; 55: 442–451.

  • 14

    Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 2012; 118: 4427–4436.

  • 15

    Canzonieri V, Volpe R, Gloghini A, et al. Mixed renal tumor with carcinomatous and fibroleiomyomatous components, associated with angiomyolipoma in the same kidney. Pathol Res Pract. 1993; 189: 951–956.

  • 16

    Kuhn E, De Anda J, Manoni S, et al. Renal cell carcinoma associated with prominent angioleiomyoma-like proliferation: report of 5 cases and review of the literature. Am J Surg Pathol. 2006; 30: 1372–1381.

  • 17

    Shannon BA, Cohen RJ, Segal A, et al. Clear cell renal cell carcinoma with smooth muscle stroma. Hum Pathol. 2009; 40: 425–429.

  • 18

    Smith SC, Trpkov K, Chen YB, et al. Tubulocystic carcinoma of the kidney with poorly differentiated foci: a frequent morphologic pattern of fumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol. 2016; 40: 1457–1472.

  • 19

    Warburg O. On the origin of cancer cells. Science 1956; 123: 309–314.

  • 20

    Trpkov K, Hes O, Agaimy A, et al. Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome. Am J Surg Pathol. 2016; 40: 865–875.

  • 21

    Menko FH, Maher ER, Schmidt LS, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer 2014; 13: 637–644.

  • 22

    Hes O, Condom Mundo E, Peckova K, et al. Biphasic squamoid alveolar renal cell carcinoma: a distinctive subtype of papillary renal cell carcinoma? Am J Surg Pathol. 2016; 40: 664–675.

  • 23

    Trpkov K, Athanazio D, Magi-Galluzzi C, et al. Biphasic papillary renal cell carcinoma is a rare morphological variant with frequent multifocality: a study of 28 cases. Histopathology 2018; 72: 777–785.

  • 24

    Trpkov K, Hes O, Bonert M, et al. Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol. 2016; 40: 60–71.

  • 25

    Tretiakova MS. Eosinophilic solid and cystic renal cell carcinoma mimicking epithelioid angiomyolipoma: series of 4 primary tumors and 2 metastases. Hum Pathol. 2018; 80: 65–75.

  • 26

    Trpkov K, Abou-Ouf H, Hes O, et al. Eosinophilic solid and cystic renal cell carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity. Am J Surg Pathol. 2017; 41: 1299–1308.

  • 27

    Hes O, de Souza TG, Pivovarcikova K, et al. Distinctive renal cell tumor simulating atrophic kidney with 2 types of microcalcifications. Report of 3 cases. Ann Diagn Pathol. 2014; 18: 82–88.

  • 28

    Oshiro Y, Hida AI, Tamiya S, et al. Bilateral atrophic kidney-like tumors. Pathol Int. 2014; 64: 478–480.

  • 29

    Shen R, Wen P. Clear cell renal cell carcinoma with syncytial giant cells: a case report and review of the literature. Arch Pathol Lab Med. 2004; 128: 1435–1438.

  • 30

    Williamson SR, Kum JB, Goheen MP, et al. Clear cell renal cell carcinoma with a syncytial-type multinucleated giant tumor cell component: implications for differential diagnosis. Hum Pathol. 2014; 45: 735–744.

  • 31

    Rotterova P, Martinek P, Alaghehbandan R, et al. High-grade renal cell carcinoma with emperipolesis: clinicopathological, immunohistochemical and molecular-genetic analysis of 14 cases. Histol Histopathol. 2018; 33: 277–287.

  • 32

    Skenderi F, Ulamec M, Vanecek T, et al. Warthin-like papillary renal cell carcinoma: clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases. Ann Diagn Pathol. 2017; 27: 48–56.

  • 33

    Pitra T, Pivovarcikova K, Alaghehbandan R, et al. Chromosomal numerical aberration pattern in papillary renal cell carcinoma. Ann Diagn Pathol. 2019; 40: 189–199.

  • 34

    Davis CF, Ricketts CJ, Wang M, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 2014; 26: 319–330.

  • 35

    Kuroda N, Tanaka A, Yamaguchi T, et al. Chromophobe renal cell carcinoma, oncocytic variant: a proposal of a new variant giving a critical diagnostic pitfall in diagnosing renal oncocytic tumors. Med Mol Morphol. 2013; 46: 49–55.

  • 36

    Trpkov K, Williamson SR, Martinek P, et al. Oncocytic renal tumors with CD117 negative, cytokeratin 7 positive immunoprofile are different from eosinophilic chromophobe renal cell carcinoma and oncocytoma. Mod Pathol. 2018; 31(Suppl S2): 393A.

  • 37

    He H, Trpkov K, Martinek P, et al. “High-grade oncocytic renal tumor”: morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Arch. 2018; 473: 725–738.

  • 38

    Trpkov K, Bonert M, Gao Y, et al. High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex. Histopathology 2019; 75: 440–442.

  • 39

    Turajlic S, Xu H, Litchfield K, et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal. Cell 2018; 173: 595–610.e11.

  • 40

    Hakimi AA, Tickoo SK, Jacobsen A, et al. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Mod Pathol. 2015; 28: 845–853.

  • 41

    Ohe C, Kuroda N, Matsuura K, et al. Chromophobe renal cell carcinoma with neuroendocrine differentiation/morphology: a clinicopathological and genetic study of three cases. Hum Pathol Case Rep. 2014; 1: 31–39.

  • 42

    Peckova K, Martinek P, Ohe C, et al. Chromophobe renal cell carcinoma with neuroendocrine and neuroendocrine-like features. Morphologic, immunohistochemical, ultrastructural, and array comparative genomic hybridization analysis of 18 cases and review of the literature. Ann Diagn Pathol. 2015; 19: 261–268.

  • 43

    Harrison WJ, Andrici J, Maclean F, et al. Fumarate hydratase-deficient uterine leiomyomas occur in both the syndromic and sporadic settings. Am J Surg Pathol. 2016; 40: 599–607.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Oct 2020 0 27 29
Nov 2020 0 43 27
Dec 2020 0 25 25
Jan 2021 0 25 24
Feb 2021 0 29 44
Mar 2021 0 24 22
Apr 2021 0 8 11